%20(2).png)
Information Page
Can metastasis be stopped?
Find out if your dog qualifies for Tina's Trial:
EGFR/HER2 Vaccine Study
A new cancer immunotherapy developed by researchers at Yale U is being evaluated in this study led by Therajan LLC
RECENT UPDATES:
Oct 28, 2024
At the recent Veterinary Cancer Society meeting, the following median survival times were reported.
-
Osteosarcoma patients without surgery (with radiation and the vaccine) - 357 days
-
Osteosarcoma patients without surgery (with radiation, no vaccine) -136 days
-
Hemangiosarcoma stage 1 patients with vaccine - 236 days
-
Hemangiosarcoma stage 2 patients with vaccine - 215 days
These are still early results with small number of patients.
Oct 24, 2024
A new clinical trial site in Ventura, California has been added. See the updated list below.
July 20, 2024
BARC clinic in Seattle is enrolling patients for vaccine + GILVETMAB study. This Gilvetmab study is only open to HEMANGIOSARCOMA patients. Learn more about Gilvetmab here.
Learn more here: https://www.youtube.com/@caninecanceralliance
Why immunotherapy? It may
-
Prevent the recurrence and spreading of cancer
-
Help when surgery is not possible, or if chemotherapy doesn't work
-
Slow or reverse cancer metastasis
Maggie was diagnosed with osteosarcoma in Jan 2020 and got conventional treatment plus the vaccine. She is still cancer-free.
Ranger's cancer kept on spreading, even after surgery and chemotherapy. But his tumors shrank and disappeared after the EGFR/HER2 vaccine treatment.
Codi's metastatic osteosarcoma began to disappear a month after he received the EGFR/HER2 vaccine injection. He enjoyed 3 extra years as a healthy, happy pup.
How does it work?
-
Safely activates the immune system against cancer cells that are over-expressing EGFR and HER2 proteins.
-
The vaccine has already been given to over 600 canine patients. Minimum side effects reported.
-
May help with many different cancer types. Preliminary data for osteosarcoma and hemangiosarcoma published.
-
Watch a recent update from the team.
Limitations and Challenges
-
Today's immunotherapy cannot guarantee every dog will become a long-term survivor.
-
Researchers are investigating different ways to safely enhance the efficacy and increase the number of responders.
Learn about strategies that might enhance efficacy of immunotherapy treatments.
Please contact us at info@ccralliance.org
with any questions.
Clinical Trial Locations L
Washington State University Veterinary Teaching Hospital
IVO Integrative Veterinary Oncology
Ventura
Edmonds
Pullman
Salt Lake City
Cleveland
McMurray
Fairfax
Phoenix
Chicago
Richmond
Stamford
CA
WA
WA
UT
OH
PA
OH
AZ
IL
VA
CT
Dr Lori Cesario
Dr Chelsea Tripp
Dr Rance Sellon
Dr Katie Wright
Dr Rochelle Prudic
Dr Christine Anderson
Dr Karina Valerius
Dr Betsy Hershey
Dr Roberta Portela
Dr Melissa Miller
Dr. Lindsay Thalheim
(805)-918-8436
(425) 697-2272
(509) 335-0711
(385) 341-4444
(216) 362-6000
(724) 717-2273
(513) 561-0069
(602) 841-0626
(773) 281-7110
Please note that combined vaccine + gilvetmab study is only open to hemangiosarcoma patients at Bridge Animal Referral Center.
Click here to open google map
Stay Involved
How can I best help my pup respond to the vaccine?
Anything to avoid? Can dietary intervention help?
What's the relationship between cancer and gut microbiome?
Will checkpoint inhibitors become available?
How can I contribute my pup's samples to the study?
Receive email updates and invitation to future zoom sessions.
Please contact us at info@ccralliance.org
with any questions.
Updates and Resources
Webinars
-
Webinar and Q&A session on Jan 30, 2024. Watch here.
-
Webinar with Prof Mark Mamula on May 13, 2024. Watch here.
-
Hemangiosarcoma Research Webinar. Watch here.
-
The Promise of Immunotherapy Webinar. Watch here.
Other Resources
-
Read our article on fasting and ketogenic diet, and cancer treatments.
-
Yale's EGFR/HER2 Vaccine Helps Dogs With Metastasis?! (9min read) An Introduction
-
EGFR/HER2 Vaccine Clinical Study Status: Tina’s Trial Video ( 25 min )
-
Vaccines and immunotherapy for dogs with osteosarcoma (2 min read) This article describes all cancer immunotherapy treatments for dogs with osteosarcoma studies that are available in the US.
Papers and Presentations
-
2024 Poster Presentation, Veterinary Cancer Society Annual Meeting in Orlando
-
2024 Poster Presentation, World Veterinary Cancer Congress in Tokyo
-
2023 Presentation Veterinary Cancer Society Mid-Year Meeting
-
2022 Presentation Veterinary Cancer Society Annual Meeting
-
2021 Publication: Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer